BillionToOne (NASDAQ: BLLN) CPO sells 8,000 shares under 10b5-1 plan
Rhea-AI Filing Summary
BillionToOne, Inc. Chief Product Officer Sakakibara Shan Riku reported a mix of stock sales and an option exercise in Class A Common Stock. The insider sold a total of 8,000 shares in open-market transactions at $110.00 per share.
On the same date, the insider also exercised stock options to acquire 4,000 shares of Class A Common Stock at an exercise price of $8.65 per share. The filing notes these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance rather than timed discretionarily.
Positive
- None.
Negative
- None.
Insights
Pre-planned sales with a small option exercise look routine.
The Chief Product Officer of BillionToOne executed an exercise-and-sell pattern: exercising options for 4,000 shares at $8.65 per share and selling 8,000 shares of Class A Common Stock at $110.00 per share.
The filing states these trades were made under a Rule 10b5-1 trading plan adopted on March 6, 2026, suggesting the timing was predetermined rather than reactive to short-term news. The options exercised were fully vested and had an expiration date in 2033.
Because the transactions are pre-planned and combine an option exercise with open-market sales, they generally align with routine liquidity and compensation management. Subsequent filings may provide additional context on remaining equity and option holdings.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 4,000 | $8.65 | $35K |
| Exercise | Class A Common Stock | 4,000 | $8.65 | $35K |
| Sale | Class A Common Stock | 4,000 | $110.00 | $440K |
| Sale | Class A Common Stock | 4,000 | $110.00 | $440K |
Footnotes (2)
- F1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.
- F2. The options are fully vested and exercisable. The terms of the underlying option grant are as previously reported on the Reporting Person's Form 3 filed on November 5, 2025.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
Stock Option (right to buy) financial
Exercise or conversion of derivative security financial
open-market sale financial
Class A Common Stock financial
FAQ
What insider transactions did BLLN Chief Product Officer report on this Form 4?
Were the BLLN insider’s transactions made under a Rule 10b5-1 plan?
What type of derivative security did the BLLN insider exercise?
AI-generated analysis. How Rhea-AI works. Not financial advice.